T-lymphocyte cell therapy - Green Cross Cell

Drug Profile

T-lymphocyte cell therapy - Green Cross Cell

Alternative Names: Activated T-lymphocytes - Green Cross Cell; Activated T-lymphocytes - Innocell; Immuncell-LC; Inno-LC-01; T-lymphocyte cell therapy - Innocell

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innocell Corporation
  • Developer Green Cross Cell
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatocellular carcinoma
  • Phase III Glioblastoma
  • Phase II Colorectal cancer; Pancreatic cancer
  • Preclinical Cervical cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 27 Nov 2017 Discontinued - Preclinical for Ovarian cancer in South Korea (IV)
  • 04 Jul 2017 Green Cross Cell completes a phase II trial for Hepatocellular carcinoma (Adjuvant therapy) in South Korea (IV) (NCT01897610)
  • 01 May 2017 Phase-II clinical trials in Pancreatic cancer (Second-line therapy or greater) in South Korea (IV) (Green Cross Cell pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top